46 completed. 46 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 46 | Completed 46 |
| Phase 2 | 2 | Completed 2 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder | Phase 3 | Completed | Dong-A ST Co., Ltd. | 607 | 2022-05-12 | 2024-06-26 |
| To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder JLP-2002 A mg, Placebo - Overactive Bladder | Phase 3 | Completed | Jeil Pharmaceutical Co., Ltd. | 210 | 2020-05-21 | 2022-01-28 |
| Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia Vibegron - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 276 | 2019-09-19 | 2024-08-21 |
| Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) Vibegron, Placebo - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1105 | 2019-03-26 | 2024-08-07 |
| An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Vibegron, placebos, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 506 | 2018-06-14 | 2021-03-18 |
| A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) vibegron, Vibegron placebo, Tolterodine Tartrate ER - Overactive Bladder | Phase 3 | Completed | Urovant Sciences GmbH | 1530 | 2018-03-26 | 2021-03-04 |
| Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease solifenacin, Pelvic floor muscle exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 3 | Completed | VA Office of Research and Development | 77 | 2018-03-01 | 2024-09-24 |
| Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder. Uritos®, Urotol® - Overactive Bladder | Phase 3 | Completed | R-Pharm | 300 | 2016-07-18 | 2019-05-21 |
| Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. Fesoterodine - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 26 | 2015-10-01 | 2019-07-30 |
| Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB THVD-201, Placebo(For THVD-201), Detrusitol 2mg tablet - Overactive Bladder | Phase 3 | Completed | SK Chemicals Co., Ltd. | 384 | 2015-01-01 | 2017-01-12 |
| Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children Fesoterodine, Oxybutynin XL - Overactive Bladder | Phase 3 | Completed | Stéphane Bolduc | 62 | 2014-12-01 | 2019-07-30 |
| Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women Darifenacin, Physiotherapy - Overactive Bladder | Phase 3 | Completed | Universidad de Valparaiso | 80 | 2014-05-01 | 2016-05-02 |
| A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin - Urinary Bladder Overactive, Overactive Bladder | Phase 3 | Completed | Astellas Pharma Europe B.V. | 1829 | 2014-03-17 | 2024-10-31 |
| This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate - Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases | Phase 3 | Completed | Astellas Pharma Europe B.V. | 3527 | 2013-11-05 | 2024-10-31 |
| Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder Mirabegron - Overactive Bladder, Urinary Incontinence | Phase 3 | Completed | CHU de Quebec-Universite Laval | 35 | 2013-04-01 | 2018-04-24 |
| Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder mirabegron - Overactive Bladder, Urinary Incontinence | Phase 3 | Completed | CHU de Quebec-Universite Laval | 58 | 2013-04-01 | 2018-06-20 |
| A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence BOTOX®, solifenacin, Botox placebo (normal saline) - Overactive Bladder, Urinary Incontinence | Phase 3 | Completed | Allergan | 356 | 2013-03-01 | 2019-04-23 |
| Combined Behavioral and Drug Treatment of Overactive Bladder in Men Behavioral training, Tolterodine + tamsulosin, Combined Behavioral + Drug Therapy - Overactive Bladder, Lower Urinary Tract Symptoms | Phase 2 / Phase 3 | Completed | University of Alabama at Birmingham | 204 | 2010-07-01 | 2017-05-25 |
| Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream. Oxybutynin (Oxytrol, BAY839380) - Overactive Bladder | Phase 3 | Completed | Bayer | 855 | 2010-05-25 | 2020-10-20 |
| Anticholinergic vs. Botox Comparison Study Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg - Urge Urinary Incontinence, Overactive Bladder | Phase 3 | Completed | NICHD Pelvic Floor Disorders Network | 249 | 2010-03-01 | 2018-05-02 |
Showing 20 of 46. Sign in to see all of them.
Urinary Bladder, Overactive (46) · Urinary Incontinence (10) · Urinary Incontinence, Urge (7) · Lower Urinary Tract Symptoms (4) · Nocturia (3) · Prostatic Hyperplasia (2) · Urologic Diseases (2) · Male Urogenital Diseases (1) · Parkinson Disease (1) · Syndrome (1)
Female Urogenital Diseases (46) · Female Urogenital Diseases and Pregnancy Complications (46) · Pathological Conditions, Signs and Symptoms (46) · Signs and Symptoms (46) · Urinary Bladder Diseases (46) · Urogenital Diseases (46) · Urological Manifestations (46) · Male Urogenital Diseases (45) · Urologic Diseases (44) · Lower Urinary Tract Symptoms (42) · Urination Disorders (16) · Urinary Incontinence (6) · Genital Diseases (2) · Genital Diseases, Male (2) · Prostatic Diseases (2)
Tolterodine Tartrate (10) · Botulinum Toxins, Type A (9) · Solifenacin Succinate (7) · fesoterodine (7) · Saline Solution (5) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (4) · mirabegron (4) · imidafenacin (3) · oxybutynin (3) · propiverine (2) · Behavior Therapy (1) · DA-8010 (1) · Drug Therapy (1) · Physical Therapy Modalities (1) · Tablets (1)
Allergan (7) · Pfizer (6) · Urovant Sciences GmbH (4) · Astellas Pharma Europe B.V. (2) · CHU de Quebec-Universite Laval (2) · Duramed Research (2) · Ono Pharmaceutical Co., Ltd. (2) · Stéphane Bolduc (2) · APOGEPHA Arzneimittel GmbH (1) · Astellas Pharma Inc (1) · Bayer (1) · Boston Scientific Corporation (1) · Corewell Health East (1) · Dong-A ST Co., Ltd. (1) · Jeil Pharmaceutical Co., Ltd. (1)
United States (28) · Canada (14) · Poland (13) · Belgium (10) · Germany (10) · Czechia (9) · Russia (9) · South Korea (9) · United Kingdom (8) · Spain (7) · Ukraine (7) · Hungary (6) · Italy (6) · Singapore (6) · Slovakia (6)
Alexis Te (1) · Anthony Visco, MD (1) · Benjamin Li, PhD (1) · Daniela Marschall-Kehrel, MD (1) · Elizabeth Camille Vaughan, MD MS (1) · Kathryn L Burgio, PhD (1) · Kathryn L. Burgio, PhD MA BA (1) · Kenneth Peters, MD (1) · Kim Caramelli, MS (1) · Kyu Sung Lee (1)
PMID 37160401, PMID 35881009, PMID 24754838, PMID 25288099, PMID 26231052, PMID 37811598, PMID 18502028, PMID 18584946, PMID 19143854, PMID 19233423, PMID 19348029, PMID 20121659, PMID 20723260, PMID 21428726, PMID 21798658, PMID 22008247, PMID 22092152, PMID 22503020, PMID 22965657, PMID 23036134, PMID 23448285, PMID 23608668, PMID 23892704, PMID 26516810, PMID 26876327, PMID 27564385, PMID 29866467, PMID 31930360, PMID 32665528, PMID 33332699, PMID 33356445, PMID 33469832, PMID 33620895, PMID 34921665, PMID 35685566, PMID 36384907, PMID 37586052, PMID 37586057, PMID 38651909, PMID 40658410, PMID 41363221
2017 (2), 2018 (2), U01HD041249 (1), U10HD041250 (1), U10HD041261 (1), U10HD041267 (1), U10HD054136 (1), U10HD054214 (1), U10HD054215 (1), U10HD054241 (1)